Scientists have been searching for ways to make immune checkpoint inhibitors work for more people with cancer. In two trials, researchers explored a possible role for JAK inhibitors, which reduce chronic inflammation.
People with advanced endometrial cancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency. FDA also expanded approval of dostarlimab for advanced endometrial cancer.
Clinical Trials Information for Patients and Caregivers
NCI’s Center for Cancer Research (CCR) conducts hundreds of clinical trials for people with cancer, HIV, and immunodeficiency disorders at the NIH Clinical Center in Bethesda, Maryland. This page includes an overview of CCR’s clinical trials program, information for potential participants and referring physicians, patient stories, and more.
This page provides a full list of clinical trials conducted by CCR in Bethesda, Maryland. It also offers quick facts about CCR clinical trials and ways to get in touch with a CCR clinical trial specialist.
In this phase 2 trial, people with cervical cancer that has spread or come back after treatment with pembrolizumab (Keytruda) will be assigned by chance to get pembrolizumab alone or pembrolizumab plus an experimental vaccine that targets HPV. Doctors want to determine the safety of the combination and see if it helps shrink or get rid of the cancer.
This phase 2 clinical trial is testing chemotherapy and an immunotherapy vaccine before surgery for people with newly diagnosed throat cancer that test positive for HPV. All people in the trial will receive chemotherapy. Half will also get an experimental HPV-targeted vaccine before surgery. Doctors want to how many people in each treatment group have their tumors shrink or go away.
This phase 1/2 trial will test an experimental drug called PLX038 in people with tumors that start in the central nervous system (primary CNS tumors) and that are growing or have started to regrow after treatment. Doctors will assess the safety and determine the best dose of the drug. They will also see if it causes tumors to stop growing in people with changes in the MYC or MYCN genes.
